Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8989746 | 0.96 | CCR3 (0.43) | CCR3SLC6A2SLC6A4SLC6A3MAPT | |
| SCHEMBL8990132 | 0.94 | CCR3 (0.43) | CCR3SLC6A2SLC6A4SLC6A3NPC1 | |
| SCHEMBL8990045 | 0.92 | RAB9A (0.41) | CCR3SLC6A2SLC6A4SLC6A3NPC1 | |
| SCHEMBL8989749 | 0.90 | MAPT (0.46) | CCR3SLC6A2SLC6A4SLC6A3NPC1 | |
| SCHEMBL8989766 | 0.89 | MAPT (0.47) | CCR3NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL8989600 | 0.88 | RECQL (0.41) | CCR3SLC6A2SLC6A4SLC6A3MAPT | |
| SCHEMBL8988043 | 0.86 | MAPT (0.43) | CCR3MAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL8989648 | 0.85 | MEN1 (0.43) | CCR3SLC6A2SLC6A4SLC6A3NPC1 | |
| SCHEMBL8990016 | 0.85 | DRD4 (0.44) | SLC6A2SLC6A4SLC6A3MAPTALDH1A1 | |
| SCHEMBL11995848 | 0.84 | MAPT (0.41) | NPC1MAPTRAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431702-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8309729-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188279-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | CCR3 2650/4885SLC6A2 283/4885SLC6A4 640/4885 |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | CCR3 2650/4885SLC6A2 283/4885SLC6A4 640/4885 |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | CCR3 2650/4885SLC6A2 283/4885SLC6A4 640/4885 |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | CCR3 2650/4885SLC6A2 283/4885SLC6A4 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.